EyePoint Pharmaceuticals (EYPT) Misses Q1 EPS by 17c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q1 EPS of ($0.99), $0.17 worse than the analyst estimate of ($0.82). Revenue for the quarter came in at $696 thousand versus the consensus estimate of $1.01 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Essential Properties Realty Trust (EPRT) Reiterated at Buy by Stifel